Phthalazine derivatives as P2X3 inhibitors
AssigneeChiesi Farmaceutici S.p.A.
InventorsClaudio Fiorelli, Paolo Bruno, Matteo Biagetti, Charles Baker-Glenn, Hervè Van De Poöel
Life of this patent
Estimating the term…
Abstract
The present invention relates to compounds of formula (I) inhibiting P2X purinoceptor 3; particularly the invention relates to compounds that are phthalazine derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of many disorders associated with P2X3 receptors mechanisms, such as respiratory diseases including cough, asthma, idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD).
Claims9
A compound of formula (I)
- wherein
- Z is selected from the group consisting of (5-6 membered)-heteroaryl and aryl, wherein any of such heteroaryl and aryl may be optionally substituted by one or more selected from the group consisting of (C1-C3) alkyl- and halo;
- R1 is H or (C1-C4) alkyl;
- R2 is selected from the group consisting of heteroaryl and (C3-C8) cycloalkyl-, wherein any of such heteroaryl may be optionally substituted by one or more selected from the group consisting of (C1-C3) alkyl, (C1-C6) haloalkyl and halo;
- R3 is H or (C1-C4) alkyl;
- Y is selected from the group consisting of H, (C1-C4) alkyl-, (C3-C8) cycloalkyl-, (C3-C8) heterocycloalkyl, and (C3-C8) heterocycloalkyl-(C1-C4) alkyl-,
- or stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof.
Dependencies are inferred from the claim text.